Controlled Attenuation Parameters to Assess Liver Steatosis in Obese Patients with Polycystic Ovary Syndrome

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Sep 18

PMID 37720537

Authors

Dongxu Wang

Nan Nan

Hao Bing

Bing He

Affiliations

Soon will be listed here.

Abstract

Objectives: This study was performed to investigate the changes and influencing factors of liver controlled attenuation parameter (CAP) in obese patients with polycystic ovary syndrome (PCOS), and to determine the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD) in PCOS patients with obesity.

Methods: Forty-one PCOS patients with obesity and twenty age- and body mass index (BMI)-matched control women without PCOS were enrolled in this study. General data, body composition, biochemical parameters, sex hormones, and liver CAP in the two groups were collected and compared. Liver CAP was measured using transient elastography.

Results: NAFLD was more common in the Obese PCOS group than in the control group (75.61% vs. 45.00%, =0.018). Compared to the control group, the obese PCOS group showed apparent increases in alanine transaminase (ALT), aspartate transaminase (AST), CAP, triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), totle testosterone (TT), free androgen index (FAI), fasting insulin (FIns), and homeostasis model assessment-insulin resistance (HOMA-IR), along with lower high-density lipoprotein cholesterol (HDL-C) and sex hormone binding globulin (SHBG) levels. In addition, as shown by Spearman analysis, liver CAP in PCOS patients with obesity had a positive correlation with ALT, AST, TG, TT, FAI, FIns, and HOMA-IR, and a negative correlation with SHBG. Logistic regression analysis showed that TG, TT, FIns, and HOMA-IR were risk factors for NAFLD, while TT was an independent risk factor for NAFLD in PCOS patients with obesity.

Conclusion: PCOS patients with obesity had a significantly higher prevalence of NAFLD. Furthermore, in PCOS patients with obesity, liver CAP was associated with disorders of lipid metabolism, insulin resistance, and hyperandrogenemia, with elevated testosterone levels being an independent risk factor for NAFLD in PCOS patients with obesity.

Citing Articles

The signaling pathways in obesity-related complications.

Chandrasekaran P, Weiskirchen R J Cell Commun Signal. 2024; 18(2):e12039.

PMID: 38946722 PMC: 11208128. DOI: 10.1002/ccs3.12039.

References

Zhang J, Hu J, Zhang C, Jiao Y, Kong X, Wang W . Analyses of risk factors for polycystic ovary syndrome complicated with non-alcoholic fatty liver disease. Exp Ther Med. 2018; 15(5):4259-4264. PMC: 5920378. DOI: 10.3892/etm.2018.5932. View

Wang D, He B . Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome. Diabetes Metab Syndr Obes. 2022; 15:1281-1291. PMC: 9048954. DOI: 10.2147/DMSO.S362424. View

Seidu T, McWhorter P, Myer J, Alamgir R, Eregha N, Bogle D . DHT causes liver steatosis via transcriptional regulation of SCAP in normal weight female mice. J Endocrinol. 2021; 250(2):49-65. PMC: 8240729. DOI: 10.1530/JOE-21-0040. View

Moghetti P, Tosi F . Insulin resistance and PCOS: chicken or egg?. J Endocrinol Invest. 2020; 44(2):233-244. DOI: 10.1007/s40618-020-01351-0. View

Cui P, Hu W, Ma T, Hu M, Tong X, Zhang F . Long-term androgen excess induces insulin resistance and non-alcoholic fatty liver disease in PCOS-like rats. J Steroid Biochem Mol Biol. 2021; 208:105829. DOI: 10.1016/j.jsbmb.2021.105829. View

Cai J, Wu C, Zhang Y, Wang Y, Xu W, Lin T . High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance. Int J Obes (Lond). 2017; 41(9):1341-1347. DOI: 10.1038/ijo.2017.116. View

Wong G . Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol. 2014; 20(3):228-36. PMC: 4197170. DOI: 10.3350/cmh.2014.20.3.228. View

Kosmalski M, Frankowski R, Deska K, Rozycka-Kosmalska M, Pietras T . Exploring the Impact of Nutrition on Non-Alcoholic Fatty Liver Disease Management: Unveiling the Roles of Various Foods, Food Components, and Compounds. Nutrients. 2023; 15(13). PMC: 10343927. DOI: 10.3390/nu15132838. View

Qu Y, Song Y, Chen C, Fu Q, Shi J, Xu Y . Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol. 2021; 12(4):e00323. PMC: 8049161. DOI: 10.14309/ctg.0000000000000323. View

10.

Lahelma M, Luukkonen P, Qadri S, Ahlholm N, Lallukka-Bruck S, Porthan K . Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity. Nutrients. 2021; 13(1). PMC: 7827136. DOI: 10.3390/nu13010169. View

11.

Laurent M, Hammond G, Blokland M, Jardi F, Antonio L, Dubois V . Sex hormone-binding globulin regulation of androgen bioactivity in vivo: validation of the free hormone hypothesis. Sci Rep. 2016; 6:35539. PMC: 5066276. DOI: 10.1038/srep35539. View

12.

Fujii H, Kawada N, Japan Study Group Of Nafld Jsg-Nafld . The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2020; 21(11). PMC: 7312931. DOI: 10.3390/ijms21113863. View

13.

Guo H, Ma C, Wu X, Pan C . Functional Status of Pancreatic and Cells in Type 2 Diabetes Mellitus Patients with Different Plasma Triglyceride Levels: A Retrospective Analysis. Int J Endocrinol. 2021; 2021:9976067. PMC: 8387189. DOI: 10.1155/2021/9976067. View

14.

Zhang J, Xing C, Cheng X, He B . Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. Front Endocrinol (Lausanne). 2022; 13:1003238. PMC: 9486461. DOI: 10.3389/fendo.2022.1003238. View

15.

Deswal R, Narwal V, Dang A, Pundir C . The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. J Hum Reprod Sci. 2021; 13(4):261-271. PMC: 7879843. DOI: 10.4103/jhrs.JHRS_95_18. View

16.

Tong C, Wu Y, Zhang L, Yu Y . Insulin resistance, autophagy and apoptosis in patients with polycystic ovary syndrome: Association with PI3K signaling pathway. Front Endocrinol (Lausanne). 2023; 13:1091147. PMC: 9800521. DOI: 10.3389/fendo.2022.1091147. View

17.

Liu H, Niu Q, Wang T, Dong H, Bian C . Lipotoxic hepatocytes promote nonalcoholic fatty liver disease progression by delivering microRNA-9-5p and activating macrophages. Int J Biol Sci. 2022; 17(14):3745-3759. PMC: 8898344. DOI: 10.7150/ijbs.57610. View

18.

Charan J, Biswas T . How to calculate sample size for different study designs in medical research?. Indian J Psychol Med. 2013; 35(2):121-6. PMC: 3775042. DOI: 10.4103/0253-7176.116232. View

19.

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.004. View

20.

Zhang Y, Meng F, Sun X, Sun X, Hu M, Cui P . Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver. Oncotarget. 2018; 9(26):18180-18197. PMC: 5915065. DOI: 10.18632/oncotarget.24477. View